Have a personal or library account? Click to login
Management of malignant bowel obstruction in patients with advanced cancer at the end of life Cover

Management of malignant bowel obstruction in patients with advanced cancer at the end of life

Open Access
|Mar 2026

References

  1. Yu K, Liu L, Zhang X, Zhang Z, Rao B, Chen Y, et al. Surgical and conservative management of malignant bowel obstruction: outcome and prognostic factors. Cancer Manag Res 2020; 12: 7797-803. doi: 10.2147/CMAR.S256219
  2. Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001; 9: 223-33. doi: 10.1007/s005200000198
  3. Davis M, Hui D, Davies A, Ripamonti C, Capela A, DeFeo G, et al. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Support Care Cancer 2021; 29: 808996. doi: 10.1007/s00520-021-06438-9
  4. Franke AJ, Iqbal A, Starr JS, Nair RM, George TJ. Management of malignant bowel obstruction associated with GI cancers. J Oncol Pract 2017; 13: 426-34. doi: 10.1200/JOP.2017.022210
  5. Cole JM, Khan SZ, Marks JM, Armstrong AJ, Zanotti KM, Juza RM. Enhanced gastric decompression for palliation of malignant bowel obstruction. Surg Endosc 2023; 37: 4000-4. doi: 10.1007/s00464-022-09554-7
  6. Pameijer CR, Mahvi DM, Stewart JA, Weber SM. Bowel obstruction in patients with metastatic cancer: does intervention influence outcome? Int J Gastrointest Cancer 2005; 35: 127-34. doi: 10.1385/IJGC:35:2:127
  7. Daniele A, Ferrero A, Fuso L, Mineccia M, Porcellana V, Vassallo D, et al. Palliative care in patients with ovarian cancer and bowel obstruction. Support Care Cancer 2015; 23: 3157-63. doi: 10.1007/s00520-015-2694-9
  8. Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res 2012; 4: 159-69. doi: 10.2147/CMAR.S29297
  9. Sun BJ, Tennakoon L, Spain DA, Lee B. Palliative intervention for malignant bowel obstruction comes at a cost: a national inpatient study. Am Surg 2024; 90: 2848-56. doi: 10.1177/00031348241256083
  10. Madariaga A, Lau J, Ghoshal A, Dzierżanowski T, Larkin P, Sobocki J, et al. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer. Support Care Cancer 2022; 30: 4711-28. doi: 10.1007/s00520-022-06889-8
  11. Krouse RS. The international conference on malignant bowel obstruction: a meeting of the minds to advance palliative care research. J Pain Symptom Manage 2007; 34: S1-6. doi: 10.1016/j.jpainsymman.2007.04.005
  12. Sun BJ, Yue TM, Xu N, Ayala CI, Lee B. Surgical palliation for malignant bowel obstruction in preventing hospital readmission: experience of a tertiary care center. Ann Surg Oncol 2024; 31: 4858-60. doi: 10.1245/s10434-024-15318-5
  13. Horesh N, Dux JY, Nadler M, Lang A, Zmora O, Shacham-Shmueli E, et al. Stenting in malignant colonic obstruction – is it a real therapeutic option? Int J Colorectal Dis 2016; 31: 131-5. doi: 10.1007/s00384-015-2375-7
  14. Imai M, Kamimura K, Takahashi Y, Sato T, Isokawa O, Maruyama M, et al. The factors influencing long-term outcomes of stenting for malignant colorectal obstruction in elderly group in community medicine. Int J Colorectal Dis 2018; 33: 189-97. doi: 10.1007/s00384-017-2946-x
  15. Selby D, Nolen A, Sittambalam C, Johansen K, Pugash R. Percutaneous transesophageal gastrostomy (PTEG): a safe and well-tolerated procedure for palliation of end-stage malignant bowel obstruction. J Pain Symptom Manage 2019; 58: 306-10. doi: 10.1016/j.jpainsymman.2019.04.031
  16. Borowiec AM, Wang CSK, Yong E, Law C, Coburn N, Sutradhar R, et al. Colonic stents for colorectal cancer are seldom used and mainly for palliation of obstruction: a population-based study. Can J Gastroenterol Hepatol 2016; 2016: 1-8. doi: 10.1155/2016/1945172
  17. Ahn HJ, Kim SW, Lee SW, Lee SW, Lim CH, Kim JS, et al. Long-term outcomes of palliation for unresectable colorectal cancer obstruction in patients with good performance status: endoscopic stent versus surgery. Surg Endosc 2016; 30: 4765-75. doi: 10.1007/s00464-016-4804-2
  18. Rademacher C, Bechtler M, Schneider S, Hartmann B, Striegel J, Jakobs R. Self-expanding metal stents for the palliation of malignant gastric outlet obstruction in patients with peritoneal carcinomatosis. World J Gastroenterol 2016; 22: 9554-61. doi: 10.3748/wjg.v22.i43.9554
  19. Tóth R, Tóth Z, Lőczi L, Török M, Ács N, Várbíró S, et al. Management of malignant bowel obstruction in patients with gynaecological cancer: a systematic review. J Clin Med 2024; 13: 4213. doi: 10.3390/jcm13144213
  20. Neri B, Citterio N, Schiavone SC, Biasutto D, Rea R, Martino M, et al. Malignant bowel occlusion: an update on current available treatments. Cancers (Basel) 2025; 17: 1522. doi: 10.3390/cancers17091522
  21. Hisanaga T, Shinjo T, Imai K, Katayama K, Kaneishi K, Honma H, et al. Clinical guidelines for management of gastrointestinal symptoms in cancer patients: the Japanese Society of Palliative Medicine recommendations. J Palliat Med 2019; 22: 986-97. doi: 10.1089/jpm.2018.0595
  22. Tutino R, Cavaglià M, Pipitone Federico NS, De Simone V, Deiro G, Gallo G, et al. The diagnostic and therapeutic value of Gastrografin in small bowel obstructions. Front Surg 2025; 12: 1516155. doi: 10.3389/fsurg.2025.1516155
  23. Wan Bahrum WFI Bin, Hardy J, Foster K, Good P. Oral water-soluble contrast for malignant bowel obstruction: open label pilot study. BMJ Support Palliat Care 2023; 13: e794-7. doi: 10.1136/bmjspcare-2021-003444
  24. Syrmis W, Richard R, Jenkins-Marsh S, Chia SC, Good P. Oral water soluble contrast for malignant bowel obstruction. Cochrane Database Syst Rev 2018; 3: CD012014. doi: 10.1002/14651858.CD012014.pub2
  25. Zhang Y, Gao Y, Ma Q, Dang C, Wei W, Deantoni F, et al. Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in older persons with adhesive small bowel obstruction. Dig Liver Dis 2006; 38: 188-94. doi: 10.1016/j.dld.2005.10.010
  26. Branco BC, Barmparas G, Schnüriger B, Inaba K, Chan LS, Demetriades D. Systematic review and meta-analysis of the diagnostic and therapeutic role of water-soluble contrast agent in adhesive small bowel obstruction. Br J Surg 2010; 97: 470-8. doi: 10.1002/bjs.7019
  27. Heng S, Hardy J, Good P. A retrospective audit on usage of diatrizoate meglumine (Gastrografin) for intestinal obstruction or constipation in patients with advanced neoplasms. Palliat Med 2018; 32: 294-8. doi: 10.1177/0269216317726430
  28. Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage 2004; 28: 412-6. doi: 10.1016/j.jpainsymman.2004.01.007
  29. Walter M, Hansen E, Hamid S, Carozza D, Mann G, Roche C, et al. Palliative management of inoperable malignant bowel obstruction: prospective, open label, phase 2 study at an NCI comprehensive cancer center. J Pain Symptom Manage 2024; 67: 20-6. doi: 10.1016/j.jpainsymman.2023.09.014
  30. Ventafridda V, Ripamonti C, Caraceni A, Spoldi E, Messina L, De Conno F. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 1990; 76: 389-93. doi: 10.1177/030089169007600417
  31. Krouse RS. Malignant bowel obstruction. J Surg Oncol 2019; 120: 74-7. doi: 10.1002/jso.25451
  32. Velilla Echeverri DC, Gómez Díaz M, Beltrán Pachón P, Lasso Valenzuela D, Poveda Carreño S, Erazo-Muñoz M. Lidocaine infusion for malignant visceral pain: case report. BMJ Support Palliat Care 2023; 13: e974-6. doi: 10.1136/spcare-2023-004350
  33. Mudumbi SK, Leonard EV, Swetz KM. Challenges and successes in nonoperative management of high-grade malignant bowel obstruction. Ann Palliat Med 2017; 6: S95-8. doi: 10.21037/apm.2017.03.07
  34. Swenson BR, Gottschalk A, Wells LT, Rowlingson JC, Thompson PW, Barclay M, et al. Intravenous lidocaine is as effective as epidural bupivacaine in reducing ileus duration, hospital stay, and pain after open colon resection. Reg Anesth Pain Med 2010; 35: 370-6. doi: 10.1097/AAP.0b013e3181e8d5da
  35. Chen PC, Lai CH, Fang CJ, Lai PC, Huang YT. Intravenous infusion of lidocaine for bowel function recovery after major colorectal surgery: a critical appraisal through updated meta-analysis, trial sequential analysis, certainty of evidence, and meta-regression. Front Med (Lausanne) 2022; 8: 759215. doi: 10.3389/fmed.2021.759215
  36. Harvey KP, Adair JD, Isho M, Robinson R. Can intravenous lidocaine decrease postsurgical ileus and shorten hospital stay in elective bowel surgery? A pilot study and literature review. Am J Surg 2009; 198: 231-6. doi: 10.1016/j. amjsurg.2008.10.015
  37. Philip J, Lickiss N, Grant PT, Hacker NF. Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Gynecol Oncol 1999; 74: 68-73. doi: 10.1006/gyno.1999.5406
  38. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2000; 2017: CD001219. doi: 10.1002/14651858.CD001219
  39. Laval G, Girardier J, Lassaunière JM, Leduc B, Haond C, Schaerer R. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction? Palliat Med 2000; 14: 3-10. doi: 10.1191/026921600669298725
  40. Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: Twenty years after. Crit Rev Oncol Hematol 2012; 83: 388-92. doi: 10.1016/j. critrevonc.2011.12.006
  41. Khoo D, Motson R, Denman K, Hall E, Riley J, Waxman J. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994; 30: 28-30. doi: 10.1016/s0959-8049(05)80012-7
  42. Kubota H, Taguchi K, Kobayashi D, Naruyama H, Hirose M, Fukuta K, et al. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer. Asian Pac J Cancer Prev 2013; 14: 7107-10. doi: 10.7314/apjcp.2013.14.12.7107
  43. Laval G, Rousselot H, Toussaint-Martel S, Mayer F, Terrebonne É, François É, et al. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction. Bull Cancer 2012; 99: E1-9. doi: 10.1684/bdc.2011.1535
  44. Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol 2010; 40: 739-45. doi: 10.1093/jjco/hyq048
  45. Shima Y, Ohtsu A, Shirao K, Sasaki Y. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol 2008; 38: 354-9. doi: 10.1093/jjco/hyn035
  46. Massacesi C, Galeazzi G. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction. Palliat Med 2006; 20: 715-6. doi: 10.1191/0269216306070751
  47. Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993; 7: 295-9. doi: 10.1177/026921639300700406
  48. Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol 2015; 13: 50. doi: 10.1186/s12957-015-0455-3
  49. Shinjo T, Kagami R. Radiological imaging change in a malignant bowel obstruction patient treated with octreotide. Support Care Cancer 2009; 17: 753-5. doi: 10.1007/s00520-009-0608-4
  50. Fainsinger RL, Spachynski K, Hanson J, Bruera E. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 1994; 9: 12-8. doi: 10.1016/0885-3924(94)90141-4
  51. Tuca A, Roca R, Sala C, Porta J, Serrano G, González-Barboteo J, et al. Efficacy of granisetron in the antiemetic control of nonsurgical intestinal obstruction in advanced cancer: a phase II clinical trial. J Pain Symptom Manage 2009; 37: 259-70. doi: 10.1016/j.jpainsymman.2008.01.014
  52. Clark K, Lam L, Currow D. Reducing gastric secretions – a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer 2009; 17: 1463-8. doi: 10.1007/s00520-009-0609-3
  53. Thompson I. The management of nausea and vomiting in palliative care. Nurs Stand 2004; 19: 46-53. doi: 10.7748/ns2004.11.19.8.46.c3752
  54. Jeong WK, Lim SB, Choi HS, Jeong SY. Conservative management of adhesive small bowel obstructions in patients previously operated on for primary colorectal cancer. J Gastrointest Surg 2008; 12: 926-32. doi: 10.1007/s11605-007-0423-5
  55. Zucchi E, Fornasarig M, Martella L, Maiero S, Lucia E, Borsatti E, et al. Decompressive percutaneous endoscopic gastrostomy in advanced cancer patients with small-bowel obstruction is feasible and effective: a large prospective study. Support Care Cancer 2016; 24: 2877-82. doi: 10.1007/s00520-016-3102-9
  56. Campagnutta E, Cannizzaro R, Gallo A, Zarrelli A, Valentini M, De Cicco M, et al. Palliative treatment of upper intestinal obstruction by gynecological malignancy: the usefulness of percutaneous endoscopic gastrostomy. Gynecol Oncol 1996; 62: 103-5. doi: 10.1006/gyno.1996.0197
  57. Brooksbank MA, Game PA, Ashby MA. Palliative venting gastrostomy in malignant intestinal obstruction. Palliat Med 2002; 16: 520-6. doi: 10.1191/0269216302pm590oa
  58. Gauvin G, Do-Nguyen CC, Lou J, O’Halloran EA, Selesner LT, Handorf E, et al. Gastrostomy tube for nutrition and malignant bowel obstruction in patients with cancer. J Natl Compr Canc Netw 2021; 19: 48-56. doi: 10.6004/jnccn.2020.7604
  59. Papachrysos N, Shafazand M, Alkelin L, Kilincalp S, de Lange T. Outcome of self-expandable metal stents placement for obstructive colorectal cancer: 7 years’ experience from a Swedish tertiary center. Surg Endosc 2023; 37: 2653-8. doi: 10.1007/s00464-022-09761-2
  60. Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89: 1096-102. doi: 10.1046/j.1365-2168.2002.02148.x
  61. Hünerbein M, Krause M, Moesta KT, Rau B, Schlag PM. Palliation of malignant rectal obstruction with self-expanding metal stents. Surgery 2005; 137: 42-7. doi: 10.1016/j.surg.2004.05.043
  62. Spinelli P, Mancini A. Use of self-expanding metal stents for palliation of rectosigmoid cancer. Gastrointest Endosc 2001; 53: 203-6. doi: 10.1016/j.surg.2004.05.043
  63. de Gregorio MA, Mainar A, Tejero E, Tobío R, Alfonso E, Pinto I, et al. Acute colorectal obstruction: stent placement for palliative treatment – results of a multicenter study. Radiology 1998; 209: 117-20. doi: 10.1148/radiology.209.1.9769821
  64. van Hooft J, van Halsema E, Vanbiervliet G, Beets-Tan R, DeWitt J, Donnellan F, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: ESGE Clinical Guideline. Endoscopy 2014; 46: 990-1053. doi: 10.1055/s-0034-1390700
  65. Lee KM, Lim SG, Shin SJ, Kim JH, Kang DH, Kim JK, et al. Novel method of stent insertion for malignant lower rectal obstruction with proximal releasing delivery system. Gastrointest Endosc 2013; 78: 930-3. doi: 10.1016/j. gie.2013.08.018
  66. Friedland S, Hallenbeck J, Soetikno RM. Stenting the sigmoid colon in a terminally ill patient with prostate cancer. J Palliat Med 2001; 4: 153-6. doi: 10.1089/109662101750290182
  67. Feuer DJ, Broadley KE, Shepherd JH, Barton DPJ. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. Gynecol Oncol 1999; 75: 313-22. doi: 10.1006/gyno.1999.5594
  68. Badgwell BD, Smith K, Liu P, Bruera E, Curley SA, Cormier JN. Indicators of surgery and survival in oncology inpatients requiring surgical evaluation for palliation. Support Care Cancer 2009; 17: 727-34. doi: 10.1007/s00520-008-0554-6
  69. Zielinski MD, Eiken PW, Heller SF, Lohse CM, Huebner M, Sarr MG, et al. Prospective, observational validation of a multivariate small-bowel obstruction model to predict the need for operative intervention. J Am Coll Surg 2011; 212: 1068-76. doi: 10.1016/j.jamcollsurg.2011.02.023
  70. Santangelo ML, Grifasi C, Criscitiello C, Giuliano M, Calogero A, Dodaro C, et al. Bowel obstruction and peritoneal carcinomatosis in the elderly: a systematic review. Aging Clin Exp Res 2017; 29: 73-8. doi: 10.1007/s40520-016-0656-9
  71. Akbaş A. Does a selective surgical approach to malignant bowel obstruction help in palliative care patients? Turk J Trauma Emerg Surg 2023; 26: 875-82. doi: 10.14744/tjtes.2020.90250
  72. McCaffrey N, Asser T, Fazekas B, Muircroft W, Agar M, Clark K, et al. Healthrelated quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. BMC Cancer 2020; 20: 1050. doi: 10.1186/s12885-020-07549-y
  73. Helyer LK, Law CHL, Butler M, Last LD, Smith AJ, Wright FC. Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol 2007; 14: 1264-71. doi: 10.1245/s10434-006-9303-6
  74. Druml C, Ballmer PE, Druml W, Oehmichen F, Shenkin A, Singer P, et al. ESPEN guideline on ethical aspects of artificial nutrition and hydration. Clin Nutr 2016; 35: 545-56. doi: 10.1016/j.clnu.2016.02.006
  75. Patel PS, Fragkos K, Keane N, Wilkinson D, Johnson A, Chan D, et al. Nutritional care pathways in cancer patients with malignant bowel obstruction: a retrospective multi-centre study. Clin Nutr ESPEN 2024; 59: 118-25. doi: 10.1016/j.clnesp.2023.11.018
  76. Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes. J Pain Symptom Manage 2000; 19: 23-34. doi: 10.1016/s0885-3924(99)00147-5
  77. Bruera E, Hui D, Dalal S, Torres-Vigil I, Trumble J, Roosth J, et al. Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol 2013; 31: 111-8. doi: 10.1200/JCO.2012.44.6518
  78. Hoppenot C, Hlubocky FJ, Chor J, Yamada SD, Lee NK. Approach to palliative care consultation for patients with malignant bowel obstruction in gynecologic oncology: a qualitative analysis of physician perspectives. JCO Oncol Pract 2020; 16: 483-9. doi: 10.1200/JOP.19.00710
  79. Selby D, Wright F, Stilos K, Daines P, Moravan V, Gill A, et al. Room for improvement? A quality-of-life assessment in patients with malignant bowel obstruction. Palliat Med 2010; 24: 38-45. doi: 10.1177/0269216309346544
  80. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non𠄓small-cell lung cancer. N Engl J Med 2010; 363: 733-42. doi: 10.1056/NEJMoa1000678
  81. Aggarwal G, Glare P, Clarke S, Chapuis P. Palliative and shared care concepts in patients with advanced colorectal cancer. ANZ J Surg 2006; 76: 175-80. doi: 10.1111/j.1445-2197.2006.03675.x
  82. Kern H, Corani G, Huber D, Vermes N, Zaffalon M, Varini M, et al. Impact on place of death in cancer patients: a causal exploration in southern Switzerland. BMC Palliat Care 2020; 19: 160. doi: 10.1186/s12904-020-00664-4
  83. Gomes B, Higginson IJ, Calanzani N, Cohen J, Deliens L, Daveson BA, et al. Preferences for place of death if faced with advanced cancer: a population survey in seven European countries. Ann Oncol 2012; 23: 2006-15. doi: 10.1093/annonc/mdr602
DOI: https://doi.org/10.2478/raon-2026-0010 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Submitted on: Oct 14, 2025
|
Accepted on: Dec 22, 2025
|
Published on: Mar 4, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Nena Golob, Rok Petric, Maja Ebert Moltara, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

AHEAD OF PRINT